Key result
CMR T2 mapping shows ~5 ms lower septal T2 values in HCM versus controls.
Why the study?
In hypertrophic cardiomyopathy (HCM), relative ischemia from a mismatch between left ventricular mass and microvascular circulation is implicated in causing prognostic myocardial replacement fibrosis. This study investigated the value of Cardiovascular Magnetic Resonance (CMR) T2 mapping—which can identify ischemia and fibrosis—to characterize structural alterations in patients with HCM.
Does CMR parametric T2 mapping identify structural alterations and differentiate myocardial replacement fibrosis in patients with hypertrophic cardiomyopathy compared to matched controls?
Case-Control (n=123)
No
Does CMR parametric T2 mapping identify structural alterations and differentiate myocardial replacement fibrosis in patients with hypertrophic cardiomyopathy compared to matched controls?
Non-contrast CMR T2 mapping detects reduced T2 relaxation times in HCM patients—particularly those with LGE-confirmed myocardial replacement fibrosis—offering a potential contrast-free parameter to aid structural risk stratification.
Answers are grounded in this paper and cite their sources.
T2 mapping may support non-contrast fibrosis assessment in HCM; leaves open its role in risk stratification pending prospective validation.
PURPOSE: Hypertrophic cardiomyopathy (HCM) is characterized by a heterogeneous morphology and variable prognosis. A mismatch between left ventricular mass (LVM) and microvascular circulation with corresponding relative ischemia has been implicated to cause myocardial replacement fibrosis that deteriorates prognosis. Besides parametric T1 mapping, Cardiovascular Magnetic Resonance (CMR) T2* mapping is able to identify ischemia as well as fibrosis in cardiac and extracardiac diseases. Therefore, we aimed to investigate the value of T2* mapping to characterize structural alterations in patients with HCM. METHODS: CMR was performed on a 1.5 T MR imaging system (Achieva, Philips, Best, Netherlands) using a 5-channel coil in patients with HCM (n = 103, 50.6 ± 16.4 years) and in age- and gender-matched controls (n = 20, 44.8 ± 16.9 years). T2* mapping (1 midventricular short axis slice) was acquired in addition to late gadolinium enhancement (LGE). T2* values were compared between patients with HCM and controls as well as between HCM patients with- and without fibrosis. RESULTS: HCM patients showed significantly decreased T2* values compared to controls (26.2 ± 4.6 vs. 31.3 ± 4.3 ms, p < 0.001). Especially patients with myocardial fibrosis presented with decreased T2* values in comparison to those without fibrosis (25.2 ± 4.0 vs. 28.7 ± 5.3 ms, p = 0.003). A regression model including maximum wall thickness, LVM and T2* values provided good overall diagnostic accuracy of 80% to diagnose HCM with and without fibrosis. CONCLUSION: In this study, parametric mapping identified lower T2* values in HCM patients compared to controls, especially in a sub-group of patients with myocardial fibrosis. As myocardial fibrosis has been suggested to influence prognosis of patients with HCM, T2* mapping may add information for identifying a higher risk sub-group of HCM patients.
No takes yet. Share an insight, caveat, or question.
Gastl et al. (2019) conducted a case-control in Hypertrophic cardiomyopathy (HCM) (n=123). Cardiovascular magnetic resonance (CMR) T2 mapping in hypertrophic cardiomyopathy vs. Age- and gender-matched healthy controls without myocardial hypertrophy (n=20) and HCM patients without LGE fibrosis (n=28) was evaluated on Midventricular interventricular septal T2 relaxation time (ms) (p=<0.001). CMR T2 mapping showed lower myocardial T2 values in HCM patients compared to controls, particularly in those with fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: